Why the study?
How has the adoption and cost of direct oral anticoagulants (DOACs) compared to warfarin changed across medical specialties and regions in the US Medicare population from 2013 to 2015?
How has the adoption and cost of direct oral anticoagulants (DOACs) compared to warfarin changed across medical specialties and regions in the US Medicare population from 2013 to 2015?
DOAC adoption in the Medicare population increased rapidly from 2013 to 2015, driven largely by specialists like electrophysiologists and orthopedists, despite significantly higher costs compared to warfarin.
No takes yet. Share an insight, caveat, or question.
Accelerating Medicare DOAC adoption warrants cost monitoring; leaves open specialty-specific outcome and equity studies.
Ziakas et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: